The research team took an unusually broad, mixed-methods approach. They conducted focus groups with twelve UK-based researchers, surveyed 107 researchers and research students with confirmed institutional affiliations, and systematically analysed 785 publications linked to antibodies with objectively poor performance. The goal was to triangulate three perspectives: what researchers say they do when choosing and validating antibodies, what they actually report doing in the published literature, and what the downstream consequences are for biological samples. This between-method design allowed the authors to cross-check evidence generated from very different sources, revealing a striking gap between self-reported practice and observed behaviour.

The focus groups and survey revealed that antibody selection is driven substantially by social and pragmatic factors rather than rigorous evaluation of performance data. Previous use within the laboratory and data in the published literature were rated as the most important purchasing factors, each rated important or very important by 77.6 percent of respondents, followed by supplier reputation at 68.2 percent and citation counts at 56.1 percent. Junior researchers often simply followed supervisor direction with minimal independent evaluation. One participant admitted they had never even heard of validating antibodies until joining the study. Established habits, affordability, and the availability of free samples all shaped decisions, while the most commonly consulted form of validation data—western blot images showing a single band at the expected molecular weight—is, on its own, not robust evidence of specificity.

When it came to validation itself, the survey painted a deceptively reassuring picture. Only about one third of respondents were aware of the International Working Group for Antibody Validation (IWGAV) five-pillar framework, published in Nature Methods in 2016, which recommends genetic strategies, tagged expression, independent antibodies, immunocapture mass spectrometry, and orthogonal validation. Nevertheless, 72 percent of surveyed researchers reported having used at least one IWGAV-aligned validation method, though most relied on a single pillar and, under a stricter definition of orthogonal validation, the proportion falls to 58.9 percent. Twenty-eight percent reported no IWGAV-aligned validation at all, relying instead on basic technical controls such as isotype or secondary-only controls, and four participants reported no validation of any kind.

The published literature told a far bleaker story. The study drew on data from the YCharOS consortium, an open-science initiative that had subjected 614 commercial antibodies directed at neuroscience-relevant proteins to standardised, knockout-controlled characterisation across western blot, immunoprecipitation, and immunofluorescence. Ninety-seven of these antibodies—15.8 percent—failed in every application tested. The Leicester team then searched the literature for publications linked to these failing antibodies and analysed 785 papers. Among the 760 papers where validation status could be determined, only 120—again 15.8 percent—presented any validation evidence aligned with the IWGAV pillars. The remaining 640 papers, 84.2 percent, reported no validation whatsoever, despite employing antibodies that had failed the most definitive test available: knockout controls, in which the target protein is genetically removed and any residual antibody signal should disappear.

The sample counts extracted from these publications are sobering. Across the 640 papers without validation data, researchers reported a minimum of 8,064 animal samples—primarily mouse and rat—and 4,424 human tissue samples, along with 1,081 human primary cell samples and 400 cell lines. The authors describe these as samples at risk of waste, a deliberately careful phrase. For the global extrapolation, they reserved the term waste for the most conservative subset: samples used with antibodies that failed every tested application, lacked reported context-specific validation, and have since been withdrawn from sale by their manufacturers, rendering the associated experiments irreproducible regardless of whether validation was silently performed. Sixteen of the 35 antibodies analysed had been discontinued, and 77.1 percent carried at least one vendor-level flag such as discontinuation or a warning against use in mouse.

Applying the observed 15.8 percent failure rate to conservative estimates of 1 to 2 million distinct commercial antibodies worldwide, and multiplying by per-antibody sample consumption rates derived from the discontinued-antibody subset, the authors estimate that roughly 4 to 7 million animal samples and 6 to 11 million human tissue samples have been consumed globally without context-specific validation. These figures are explicitly lower-bound, order-of-magnitude estimates. They count only explicitly reported sample numbers, exclude unpublished research and publications predating December 2000, exclude samples used with the 19 failing antibodies that remain commercially available, and assume that antibodies which passed at least one standardised test perform reliably in every context—an assumption the authors note is almost certainly too generous, given that antibody performance varies with application, species, tissue type, and experimental conditions.

The human tissue estimates rest on the most direct evidence, because the YCharOS pipeline tested antibodies against human antigens—the same species as the tissue consumed. The animal-sample inference requires an additional step, since performance against human antigens does not automatically predict performance against orthologous proteins in other species, but convergent evidence supports the concern: many of the failing antibodies were not recommended by their own vendors for mouse use, and virtually none of the papers using them presented any validation in the experimental system employed. The authors also examined the 20 papers that did report knockout controls and found they rarely tested the same thing as the standardised characterisation; in 15 of 20, the knockout material was mouse tissue rather than the human antigen against which the antibody had failed.

Why does this happen? The researchers mapped barriers onto the COM-B behavioural model of capability, opportunity, and motivation. Survey respondents rated money (77.6 percent) and time (75.7 percent) as the most important barriers, followed by lack of supervisor support (63.6 percent) and expertise (60.7 percent). One participant characterised validation as an expensive and time-consuming hobby, and others noted that funders do not adequately account for validation costs. Motivational barriers proved equally important: when nonvalidated antibodies produce publishable results, there is little personal incentive to change, and some researchers assume that widely cited antibodies must already be adequately validated by the community. Publication bias favouring positive findings further misleads, since unexpected bands and anomalous staining patterns are often simply ignored.

Crucially, the researchers who took part strongly support structural solutions. Open data sharing of antibody performance—including negative results—received the highest support at 80.4 percent, followed by dedicated validation funding and increased visibility of negative data (both 77.6 percent), and publisher requirements for validation evidence at 70.1 percent. Participants envisioned consumer-review-style platforms where verified researchers could share antibody outcomes, alongside education at every career stage and stricter industry standards. The study’s companion Delphi consensus paper sets out a stakeholder-endorsed roadmap of actionable recommendations. The central message is that this is a well-characterised and addressable problem: demonstrating that an antibody signal is specific to its intended target is not an optional extra but a component of sound experimental design, and coordinated action by funders, publishers, manufacturers, and institutions could prevent the further, avoidable sacrifice of animal lives and human tissue donations to unreliable reagents.

Subject of Research: The ethical costs of inadequate antibody validation for animal and human tissue samples in biomedical research

Article Title: Inadequate antibody validation places substantial numbers of animal and human tissue samples at risk of waste

Article References: Biddle, M., Cooper, J., Blades, K., Ruddy, D., Krockow, E. M., & Virk, H. (2026). Inadequate antibody validation places substantial numbers of animal and human tissue samples at risk of waste. PLOS Biology, 24(10), e3003984. https://doi.org/10.1371/journal.pbio.3003984

Image Credits: AI Generated

DOI: 10.1371/journal.pbio.3003984

Keywords: antibody validation, reproducibility crisis, animal research, human tissue samples, PLOS Biology, IWGAV, knockout controls, biological sample waste, YCharOS, research ethics, biomedical reagents, open science

The scale of the problem is staggering. An estimated 28.2 billion dollars is spent each year in the United States on preclinical research that cannot be reproduced, with faulty biological reagents likely the single biggest contributor. Antibody-related failures alone are estimated to waste more than one billion dollars annually in direct economic terms, a figure that excludes the opportunity cost of misdirected scientific effort. The ethical toll is harder to price: recent estimates suggest that at least four million animal samples and six million human tissue samples have been consumed globally since 2000 in experiments using antibodies that failed independent testing, without any context-specific validation.

The technical reasons for failure are well understood. How well an antibody binds its intended target varies between applications, protocols, and cell or tissue types, so performance must be assessed for each specific context of use, a process known as validation. Independent benchmarking by the YCharOS consortium, which tests commercial antibodies against knockout cell lines as isogenic controls, quantified the likely scale of the crisis: more than 50 percent of 614 commercial antibodies targeting 65 neuroscience-related proteins failed characterisation experiments in three commonly used applications. Worse still, 88.4 percent of papers using poorly performing antibodies in immunofluorescence presented no relevant validation data, and each flawed protein target was linked to an average of roughly twelve published papers, perpetuating the use of bad reagents through the literature.

To move from diagnosis to prescription, a team led by researchers at the University of Leicester conducted a modified Delphi study, a structured consensus-building method that collects expert opinion through iterative anonymous questionnaires with controlled feedback. Thirty-two international experts were recruited through established convening bodies including the Antibody Society, YCharOS, the National Centre for the Replacement, Refinement and Reduction of Animals in Research, and the UK Reproducibility Network. The panel spanned academic biomedical research, scientific publishing, antibody manufacturing, research funding, and institutional leadership, with most participants holding senior decision-making roles. Over two rounds conducted in late 2025, the experts rated 33 proposed actions on two nine-point scales, one for effectiveness and one for feasibility of implementation by 2030, with consensus assessed using the RAND/UCLA Appropriateness Method, which flags disagreement statistically through inter-percentile ranges.

The results were striking. The panel achieved consensus on 15 actions as both effective and feasible, spanning every stakeholder group. On the institutional front, experts endorsed training in antibody validation within bioscience courses, incorporating validation expectations into research integrity and ethics review frameworks, and supporting local champions or experts who can advise colleagues and lead reproducibility workshops. These were the only stakeholder domain in which every proposed item achieved full consensus, suggesting institutions are seen as the natural foundation of reform. Panellists emphasised that training must reach senior laboratory leaders as well as students, since a trainee taught to validate antibodies will not do so if the principal investigator does not consider it a priority.

Funders received six consensus recommendations, reflecting their pivotal position before experiments ever begin. Experts agreed that grant applicants should be required to include antibody validation plans, that funded projects should carry a dedicated budget line for validation, and that funders should create or expand targeted schemes for developing and validating critical antibody-based tools. Funders should also signal the importance of antibody performance in applicant guidance, encourage deposition of validation data in open-access repositories, and formally endorse community-developed reporting standards such as the International Working Group on Antibody Validation framework and the Materials Design Analysis Reporting framework. Several further funder actions, including co-funding independent benchmarking initiatives and mandating that funded antibodies be recombinant, were rated effective but with uncertain feasibility, often because of budget constraints and misalignment with existing funding mechanisms.

Publishers and journals secured four consensus items centred on reporting. Authors should include Research Resource Identifiers for each antibody used, provide complete metadata including clone identifier, catalogue number, lot number, and vendor, and report dilution ratios and protein concentrations where possible. Journals should also establish clear validation and reporting standards that authors must meet. These items work synergistically: complete metadata enables unambiguous identification, while persistent identifiers link antibodies to characterisation databases and the wider literature. However, a cluster of more ambitious publisher interventions, including mandatory deposition of validation data in open repositories, automated tools to flag validation issues in submissions, genetic validation for critical antibodies, and specialist reproducibility editors, were all rated highly effective but hampered by editorial costs, reviewer fatigue, and infrastructure gaps. The panel rejected only one item outright: a tiered scoring system or transparency badge for antibody reporting, which slid from uncertain to infeasible between rounds amid scepticism about badge-based incentives.

The manufacturer picture was the most constrained. The single consensus recommendation was that manufacturers assign Research Resource Identifiers to their products at source, a measure panellists described as easy and potentially transformative for tracking antibody performance across the literature. But broader demands, such as performing standard validation experiments and making the data available, or shifting production toward recombinant antibodies, were rated effective yet commercially fraught. Manufacturer representatives on the panel acknowledged that leading companies already exemplify good practice while others lag behind, and warned that comprehensive validation programmes could be prohibitively expensive without corresponding market incentives, since the research antibody market operates predominantly on catalogue breadth and low unit cost rather than demonstrated quality.

From the panel’s commentary, the study team identified four interconnected barriers that explain both the persistence of the problem and the difficulty of solving it. First, diffuse ownership enables collective inaction: no single stakeholder bears the full cost of validation failures or has the authority to mandate change, producing a pattern of mutual deflection. Second, market dynamics inadequately reward quality, making the apparent cheapness of unvalidated antibodies illusory once downstream costs of failed experiments and wasted samples are counted. Third, the benefits of investment are distributed across the whole research system, making it hard for any individual funder or institution to justify spending. Fourth, coordination is genuinely hard when more than 22,000 human protein targets, millions of antibody products, and a global research community are involved, with no single authority able to impose standards.

Crucially, the experts concluded that complete alignment is not a prerequisite for progress. The 15 consensus recommendations represent actions individual stakeholders can take without waiting for others, and panellists consistently endorsed a staged sequence of enablement, expectation, and mandate, in which funders first build resources and infrastructure before requirements become effective. Much of the needed infrastructure already exists, from the RRID initiative and the YCharOS characterisation pipeline to the Only Good Antibodies Academy and a networked antibody champions model now being piloted across UK institutions. The authors caution that their panel, weighted toward the United Kingdom and United States, represents prioritised expert judgement rather than a definitive global standard, and that feasibility will vary with local policy and funding environments. But the message is clear: the tools, the standards, and now the roadmap exist, and the remaining barrier is the will to act on a problem that has cost science billions and millions of irreplaceable biological samples.

Subject of Research: Expert consensus recommendations for improving antibody validation, selection, and reporting practices in biomedical research

Article Title: Actionable solutions to address antibody validation failures

Article References: Blades, K., Biddle, M., Froud, R., Krockow, E. M., & Virk, H. (2026). Actionable solutions to address antibody validation failures. PLOS Biology, 24(10), e3003981. https://doi.org/10.1371/journal.pbio.3003981

Image Credits: AI Generated

DOI: 10.1371/journal.pbio.3003981

Keywords: antibody validation, reproducibility, Delphi study, PLOS Biology, biomedical research, RAND/UCLA method, Research Resource Identifiers, research funding, scientific publishing, antibody manufacturers, research integrity, YCharOS